Ascletis Pharma Inc. (Ascletis-B) disclosed that it repurchased 0.20 million ordinary shares on 2 June 2026 via on-exchange transactions, paying a total of HK$2.06 million. The shares were bought at prices ranging from HK$9.98 to HK$10.54, implying a volume-weighted average cost of HK$10.28 per share.

The newly repurchased shares, earmarked for cancellation, represent 0.0188% of the company’s existing 1.06 billion issued shares (excluding treasury shares). Post-transaction, Ascletis holds 7.08 million treasury shares, leaving the company’s issued share capital unchanged at 1.07 billion shares.

Including the latest buyback, Ascletis has repurchased a total of 6.49 million shares under the mandate granted on 22 May 2025, equivalent to 0.67% of the shares outstanding on the mandate date. Of these, 5.79 million shares bought between April 2025 and June 2026 remain in treasury pending cancellation.

The current repurchase falls under the existing mandate that authorises the company to buy back up to 96.28 million shares. In accordance with Hong Kong Stock Exchange rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 July 2026.

Company Secretary Chung Ming Fai confirmed that the 2 June 2026 repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the repurchase explanatory statement dated 29 April 2025.